CD133 in brain tumor: the prognostic factor.

Bin Li, Cian McCrudden, Hiu Fung Yuen, Xinping Xi, Peng Lyu, Kwok Wah Chan, Shu Dong Zhang, Hang Fai Kwok

Research output: Contribution to journalArticle

15 Citations (Scopus)
132 Downloads (Pure)

Abstract

CD133 has been shown to be an important stem cell factor that promotes glioma progression. However, the mechanism for CD133-mediated glioma progression has yet to be fully elucidated. In this study, we found that CD133 mRNA expression was a prognostic marker in three independent glioma patient cohorts, corroborating a putative role for CD133 in glioma progression. Importantly, we found that CD133 expression in glioma was highly correlated with the expression of HOX gene stem cell factors (HOXA5, HOXA7, HOXA10, HOXC4 and HOXC6). The expression of these HOX genes individually was significantly associated with survival. Interestingly, the prognostic significance of CD133 was dependent on the expression level of HOX genes, and vice versa. CD133 (p = 0.021) and HOXA7 (p = 0.001) were independent prognostic markers when the three glioma patient cohorts were combined (n = 231). Our results suggest that HOX genes may play a more important role in progression of glioma when CD133 expression is low. Furthermore, we showed that low-level expression of LIM2 in CD133-high glioma was associated with poorer survival, suggesting that LIM2 could be a therapeutic target for glioma expressing a high level of CD133. Connectivity mapping identified vinblastine and vincristine as agents that could reverse the CD133/HOX genes/LIM2-signature, and we confirmed this by in vitro analysis in glioma cell lines, demonstrating that CD133 and HOX genes were co-expressed and could be downregulated by vincristine. In conclusion, our data show that CD133 and HOX genes are important prognostic markers in glioma and shed light on possible treatment strategies for glioma expressing a high level of CD133.
Original languageEnglish
Pages (from-to)1-16
JournalOncotarget
Volume8
Issue number7
DOIs
Publication statusPublished - 31 Dec 2016

Fingerprint Dive into the research topics of 'CD133 in brain tumor: the prognostic factor.'. Together they form a unique fingerprint.

  • Cite this

    Li, B., McCrudden, C., Yuen, H. F., Xi, X., Lyu, P., Chan, K. W., Zhang, S. D., & Kwok, H. F. (2016). CD133 in brain tumor: the prognostic factor. Oncotarget, 8(7), 1-16. https://doi.org/10.18632/oncotarget.14406